Cargando…

Joint Action European Partnership for Action Against Cancer

Cancer is a major European public health issue and represents the second most important cause of death and morbidity in Europe. Moreover, as a result of constant advances in medicine, medical technology and other sciences, and due to improvements in economic circumstances, cancer survival rates are...

Descripción completa

Detalles Bibliográficos
Autores principales: Jelenc, Marjetka, Van Hoof, Elke, Albreht, Tit, Meglič, Matic, Seljak, Marija, Krnel, Sandra Radoš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542586/
https://www.ncbi.nlm.nih.gov/pubmed/23095375
http://dx.doi.org/10.1186/0778-7367-70-24
_version_ 1782255539954122752
author Jelenc, Marjetka
Van Hoof, Elke
Albreht, Tit
Meglič, Matic
Seljak, Marija
Krnel, Sandra Radoš
author_facet Jelenc, Marjetka
Van Hoof, Elke
Albreht, Tit
Meglič, Matic
Seljak, Marija
Krnel, Sandra Radoš
author_sort Jelenc, Marjetka
collection PubMed
description Cancer is a major European public health issue and represents the second most important cause of death and morbidity in Europe. Moreover, as a result of constant advances in medicine, medical technology and other sciences, and due to improvements in economic circumstances, cancer survival rates are increasing in Europe and prevalent cases (i.e. number of subjects who have experienced cancer) represent a growing proportion of the population. In order to tackle cancer efficiently throughout the European Member states, the European Commission launched the Joint Action (JA) ‘European Partnership for Action Against Cancer’ (EPAAC) facilitated by the Community Health Programme, in September 2009. EPAAC is designed to fill a gap in cooperation, collaboration and shared experiences for countries with similar needs and diverse experience in the area of their national cancer control policies. Activities and studies are tackling the main challenges of cancer control in Europe as a whole and in the Member states, including the provision of services and health system responses, human resources and research. In contrast with previous European actions in the field of cancer, EPAAC joins different partners and stakeholders at various levels ranging from Member states (including Iceland and Norway) and Regions to patient representatives.
format Online
Article
Text
id pubmed-3542586
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35425862013-01-11 Joint Action European Partnership for Action Against Cancer Jelenc, Marjetka Van Hoof, Elke Albreht, Tit Meglič, Matic Seljak, Marija Krnel, Sandra Radoš Arch Public Health Research Cancer is a major European public health issue and represents the second most important cause of death and morbidity in Europe. Moreover, as a result of constant advances in medicine, medical technology and other sciences, and due to improvements in economic circumstances, cancer survival rates are increasing in Europe and prevalent cases (i.e. number of subjects who have experienced cancer) represent a growing proportion of the population. In order to tackle cancer efficiently throughout the European Member states, the European Commission launched the Joint Action (JA) ‘European Partnership for Action Against Cancer’ (EPAAC) facilitated by the Community Health Programme, in September 2009. EPAAC is designed to fill a gap in cooperation, collaboration and shared experiences for countries with similar needs and diverse experience in the area of their national cancer control policies. Activities and studies are tackling the main challenges of cancer control in Europe as a whole and in the Member states, including the provision of services and health system responses, human resources and research. In contrast with previous European actions in the field of cancer, EPAAC joins different partners and stakeholders at various levels ranging from Member states (including Iceland and Norway) and Regions to patient representatives. BioMed Central 2012-10-24 /pmc/articles/PMC3542586/ /pubmed/23095375 http://dx.doi.org/10.1186/0778-7367-70-24 Text en Copyright ©2012 Jelenc et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jelenc, Marjetka
Van Hoof, Elke
Albreht, Tit
Meglič, Matic
Seljak, Marija
Krnel, Sandra Radoš
Joint Action European Partnership for Action Against Cancer
title Joint Action European Partnership for Action Against Cancer
title_full Joint Action European Partnership for Action Against Cancer
title_fullStr Joint Action European Partnership for Action Against Cancer
title_full_unstemmed Joint Action European Partnership for Action Against Cancer
title_short Joint Action European Partnership for Action Against Cancer
title_sort joint action european partnership for action against cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542586/
https://www.ncbi.nlm.nih.gov/pubmed/23095375
http://dx.doi.org/10.1186/0778-7367-70-24
work_keys_str_mv AT jelencmarjetka jointactioneuropeanpartnershipforactionagainstcancer
AT vanhoofelke jointactioneuropeanpartnershipforactionagainstcancer
AT albrehttit jointactioneuropeanpartnershipforactionagainstcancer
AT meglicmatic jointactioneuropeanpartnershipforactionagainstcancer
AT seljakmarija jointactioneuropeanpartnershipforactionagainstcancer
AT krnelsandrarados jointactioneuropeanpartnershipforactionagainstcancer